Jan Drews
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jan Drews has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Thomas von Hahn
Gastroenterology, Heptology and Interventional Endoscopy, Asklepios Klinik Barmbek, Hamburg, Germany
4 shared publications Peter Wohlmuth
Proresearch, Asklepios Kliniken Hamburg GmbH, Hamburg, Germany
2 shared publications- Peter Wohlmuth
ASKLEPIOS proresearch Institute , Lohmühlenstrasse 5, 20099 Hamburg
2 shared publications - Torsten Bunde
Department of Gastroenterology, Hepatology and Interventional Endoscopy, Asklepios Hospital Barmbek, Hamburg, Germany
2 shared publications Armin Küllmer
Gastroenterology, University of Freiburg, Freiburg im Breisgau, Germany
1 shared publicationCarola Güther
Gastroenterology and Rheumatology, Carl-Thiem Hospital Cottbus, Cottbus, Germany
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
Multicentre randomised controlled trial of a self-assembling haemostatic gel to prevent delayed bleeding following endoscopic mucosal resection (PURPLE Trial)
Background Prophylactic application of a haemostatic gel to the resection field may be an easy way to prevent delayed bleeding, a frequent complication after endoscopic mucosal resection (EMR). Objective We aimed to evaluate if the prophylactic application of a haemostatic gel to the resection field directly after EMR can reduce the rate of clinically significant delayed bleeding events. Design We conducted a prospective randomised trial of patients undergoing hot-snare EMR of flat lesions in the duodenum (≥10 mm) and colorectum (≥20 mm) at 15 German centres. Prophylactic clip closure was not allowed, but selective clipping or coagulation could be used prior to randomisation to treat intraprocedural bleeding or for prophylactic closure of visible vessels. Patients were randomised to haemostatic gel application or no prophylaxis. The primary endpoint was delayed bleeding within 30 days. Results The trial was stopped early due to futility after an interim analysis. The primary endpoint was analysed in 232 patients (208 colorectal, 26 duodenal). Both groups were comparable in age, sex, comorbidities and lesion characteristics. Preventive measures, such as selective clipping or coagulation, were applied prior to randomisation in 51.9% of cases, with no difference between groups. Delayed bleeding occurred in 14 cases (11.7%; 95% CI 7.1% to 18.6%) after Purastat and in 7 cases (6.3%; 95% CI 3.1% to 12.3%) in the control group (p=0.227), with no difference between colorectal and duodenal subgroups. Conclusion The application of a haemostatic gel following EMR of large flat lesions in the duodenum and colorectum does not reduce the rate of delayed bleeding.
Top Cited PapersOpen AccessMulticentre randomised controlled trial of a self-assembling haemostatic gel to prevent delayed bleeding following endoscopic mucosal resection (PURPLE Trial)
Background Prophylactic application of a haemostatic gel to the resection field may be an easy way to prevent delayed bleeding, a frequent complication after endoscopic mucosal resection (EMR). Objective We aimed to evaluate if the prophylactic application of a haemostatic gel to the resection field directly after EMR can reduce the rate of clinically significant delayed bleeding events. Design We conducted a prospective randomised trial of patients undergoing hot-snare EMR of flat lesions in the duodenum (≥10 mm) and colorectum (≥20 mm) at 15 German centres. Prophylactic clip closure was not allowed, but selective clipping or coagulation could be used prior to randomisation to treat intraprocedural bleeding or for prophylactic closure of visible vessels. Patients were randomised to haemostatic gel application or no prophylaxis. The primary endpoint was delayed bleeding within 30 days. Results The trial was stopped early due to futility after an interim analysis. The primary endpoint was analysed in 232 patients (208 colorectal, 26 duodenal). Both groups were comparable in age, sex, comorbidities and lesion characteristics. Preventive measures, such as selective clipping or coagulation, were applied prior to randomisation in 51.9% of cases, with no difference between groups. Delayed bleeding occurred in 14 cases (11.7%; 95% CI 7.1% to 18.6%) after Purastat and in 7 cases (6.3%; 95% CI 3.1% to 12.3%) in the control group (p=0.227), with no difference between colorectal and duodenal subgroups. Conclusion The application of a haemostatic gel following EMR of large flat lesions in the duodenum and colorectum does not reduce the rate of delayed bleeding.
- Open Access
- 30 March 2024
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 57 (2) , 196-202
Impact of a simple non-invasive nasal mask device on intraprocedural hypoxemia in overweight individuals undergoing upper gastrointestinal endoscopy with sedation provided by a non-anesthesiologist provider
Background/Aims: Hypoxemia is a common side effect of propofol sedation during endoscopy. Applying mild positive airway pressure (PAP) using a nasal mask may offer a simple way to reduce such events and optimize the conditions for diagnostic and therapeutic upper gastrointestinal endoscopies.Methods: We compared overweight patients (body mass index >25 kg/m2) with a nasal PAP mask or standard nasal cannula undergoing upper gastrointestinal endoscopies by non-anesthesiologists who provided propofol sedation. Outcome parameters included the frequency and severity of hypoxemic episodes.Results: We analyzed 102 procedures in 51 patients with nasal PAP masks and 51 controls. Episodes of hypoxemia (oxygen saturation [SpO2] <90% at any time during sedation) occurred in 25 (49.0%) controls compared to 8 (15.7%) patients with nasal PAP masks (p<0.001). Severe hypoxemia (SpO2 <80%) occurred in three individuals (5.9%) in both groups. The mean delta between baseline SpO2 and the lowest SpO2 recorded was significantly decreased among patients with nasal PAP mask compared to controls (3.7 and 8.2 percentage points difference, respectively). There were significantly fewer airway interventions performed in the nasal PAP mask group (15.7% vs. 41.2%, p=0.008).Conclusions: Using a nasal PAP mask may be a simple means of increasing patient safety and ease of examination.
- 30 March 2024
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 57 (2) , 196-202
Open AccessImpact of a simple non-invasive nasal mask device on intraprocedural hypoxemia in overweight individuals undergoing upper gastrointestinal endoscopy with sedation provided by a non-anesthesiologist provider
Background/Aims: Hypoxemia is a common side effect of propofol sedation during endoscopy. Applying mild positive airway pressure (PAP) using a nasal mask may offer a simple way to reduce such events and optimize the conditions for diagnostic and therapeutic upper gastrointestinal endoscopies.Methods: We compared overweight patients (body mass index >25 kg/m2) with a nasal PAP mask or standard nasal cannula undergoing upper gastrointestinal endoscopies by non-anesthesiologists who provided propofol sedation. Outcome parameters included the frequency and severity of hypoxemic episodes.Results: We analyzed 102 procedures in 51 patients with nasal PAP masks and 51 controls. Episodes of hypoxemia (oxygen saturation [SpO2] <90% at any time during sedation) occurred in 25 (49.0%) controls compared to 8 (15.7%) patients with nasal PAP masks (p<0.001). Severe hypoxemia (SpO2 <80%) occurred in three individuals (5.9%) in both groups. The mean delta between baseline SpO2 and the lowest SpO2 recorded was significantly decreased among patients with nasal PAP mask compared to controls (3.7 and 8.2 percentage points difference, respectively). There were significantly fewer airway interventions performed in the nasal PAP mask group (15.7% vs. 41.2%, p=0.008).Conclusions: Using a nasal PAP mask may be a simple means of increasing patient safety and ease of examination.
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S220-S221
Biliary Drainage in Palliative and Curative Intent in European Patients with Hilar Cholangiocarcinoma: a retrospective single center analysis
Aims Cholestasis and jaundice are common in hilar cholangiocarcinoma (CCA) and impede both surgical and medical treatments. Thus, interventional relief of cholestasis is an integral part of multimodal therapy. Data on its effectiveness are limited, mostly originating from Asia and almost exclusively focused on the palliative setting. Methods We performed a retrospective analysis of patients with hilar CCA who underwent endoscopic cholestasis treatment at a German tertiary center between 2010 and 2020. We evaluated clinical success (CS), complications and differences between patients allocated to palliative and curative treatment concepts. Results 56 patients planned for curative and 72 patients planned for palliative therapy underwent 335 interventions. In curative patients, CS was achieved more often irrespective of what definition of CS was applied (e.g. total serum bilirubin (TSB) <2: 66.1% vs. 27.8% p= 50% 76.8% vs. 51.4% p=0.003). Moreover, palliative patients were at higher risk for periinterventional complications (33.3% vs 12.5%, p=0.006). Curative therapy setting, TSB at presentation, bilateral drainage and a Bismuth Stage III or lower were predictors for CS. Conclusions Both treatment outcomes and safety are different between patients in curative vs. palliative treatment settings. Moreover, CS is below those reported in recent Asian series. We will discuss possible reasons for these differences. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S220-S221
Biliary Drainage in Palliative and Curative Intent in European Patients with Hilar Cholangiocarcinoma: a retrospective single center analysis
Aims Cholestasis and jaundice are common in hilar cholangiocarcinoma (CCA) and impede both surgical and medical treatments. Thus, interventional relief of cholestasis is an integral part of multimodal therapy. Data on its effectiveness are limited, mostly originating from Asia and almost exclusively focused on the palliative setting. Methods We performed a retrospective analysis of patients with hilar CCA who underwent endoscopic cholestasis treatment at a German tertiary center between 2010 and 2020. We evaluated clinical success (CS), complications and differences between patients allocated to palliative and curative treatment concepts. Results 56 patients planned for curative and 72 patients planned for palliative therapy underwent 335 interventions. In curative patients, CS was achieved more often irrespective of what definition of CS was applied (e.g. total serum bilirubin (TSB) <2: 66.1% vs. 27.8% p= 50% 76.8% vs. 51.4% p=0.003). Moreover, palliative patients were at higher risk for periinterventional complications (33.3% vs 12.5%, p=0.006). Curative therapy setting, TSB at presentation, bilateral drainage and a Bismuth Stage III or lower were predictors for CS. Conclusions Both treatment outcomes and safety are different between patients in curative vs. palliative treatment settings. Moreover, CS is below those reported in recent Asian series. We will discuss possible reasons for these differences. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany